Esperite (ESP) invests in multimillion largest clinical Genetic center and aims for pole position in Europe
(Thomson Reuters ONE) -
High-tech Genetic Diagnostic with Ion Torrent Now for Everyone
Geneva, Switzerland - 29 January 2015
ESPERITE, the European leader since 2000 in the stem cells life science
business, is launching unique new-generation genetic tests. Risk-free,
convenient, affordable and accurate tests with results available in a few days.
ESPERITE eases its clients the key genetic information to personalize their
health-related decisions, fostering a new culture of consumer empowerment
towards a proactive approach to health.
ESPERITE, through its predictive medicine arm GENOMA SA, is at the forefront
of technological and scientific innovation. ESPERITE is announcing a
multimillion investment to assemble the largest genetic platform for clinical
diagnostics in Europe. A highly efficient NGS platform with the capacity to
process 75'000 samples per year as of today. ESPERITE signed a supply agreement
with Thermo Fisher Life Technology to install satellite sequencing platforms in
the countries where ESPERITE operates, all connected to its NGS Cloud.
Frederic Amar, CEO of ESPERITE group: "Our dream is a reality today. We are
improving the way we understand and address human disease by
leading transformative research and translating it into tangible benefits for
society. 2015 marks the beginning of a new era for personalized medicine".
ESPERITE is leading this paradigm shift and will communicate shortly new
developments.
About ESPERITE
ESPERITE group, listed at Euronex Amsterdam and Paris, is the leading
international company in regenerative and predictive medicine, operational in
40 countries with a network of 6'000 clinics worldwide. ESPERITE serves clients
in its state-of-the-art lab facilities in Geneva coupled with ultra-modern
processing and storage facilities in Belgium, Switzerland, Germany, Dubai, South
Africa and Portugal Its family stem cell bank, CryoSave, stores almost 275'000
samples from umbilical cord blood and cord tissue.
To learn more about the ESPERITE group, or to book an interview with CEO
Frederic Amar : +31 575 548 998 - ir(at)esperite.com or visit the websites at
www.esperite.com and www.genoma.com.
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Esperite N.V. via GlobeNewswire
[HUG#1890239]
Unternehmensinformation / Kurzprofil:
Datum: 29.01.2015 - 07:57 Uhr
Sprache: Deutsch
News-ID 367723
Anzahl Zeichen: 3012
contact information:
Town:
Zutphen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 187 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Esperite (ESP) invests in multimillion largest clinical Genetic center and aims for pole position in Europe"
steht unter der journalistisch-redaktionellen Verantwortung von
Esperite N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
